Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock

Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments. Latest Ratings for VRTX Date Firm Action From To Feb 2022 RBC Capital Downgrades Outperform Sector Perform Jan 2022 BMO Capital Upgrades Market Perform Outperform Dec 2021 Wells Fargo Initiates Coverage On Overweight View…

Read More